EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION

The goal of the study: to evaluate efficiency and safety of the anti-tuberculosis drug of bedaquiline in the multimodality therapy of patients with HIV-associated tuberculosis with multiple/extensive drug resistance (MDR/XDR).Materials and methods. 14 patients were treated with the regimens containi...

Full description

Bibliographic Details
Main Author: G. S. BALASANYANTS
Format: Article
Language:Russian
Published: New Terra Publishing House 2017-10-01
Series:Туберкулез и болезни лёгких
Subjects:
Online Access:https://www.tibl-journal.com/jour/article/view/1045
_version_ 1797696721088675840
author G. S. BALASANYANTS
author_facet G. S. BALASANYANTS
author_sort G. S. BALASANYANTS
collection DOAJ
description The goal of the study: to evaluate efficiency and safety of the anti-tuberculosis drug of bedaquiline in the multimodality therapy of patients with HIV-associated tuberculosis with multiple/extensive drug resistance (MDR/XDR).Materials and methods. 14 patients were treated with the regimens containing bedaquiline. The majority of patients (12; 85.7%) received antiretroviral therapy. 11 (78.6%) patients were diagnosed with the generalized form of tuberculosis affecting two organs and more. All 14 patients were infectious: 2 had MDR TB and 12 had XDR TB, and of them, 11 had XDR TB with resistance to 8-10 anti-tuberculosis drugs.Results. 12 out of 14 patients completed the intensive phase with administration of bedaquiline. By the end of the first month of treatment intoxication symptoms disappeared in 50.0% of patients, and by the end of the second month, they remitted in 83.5%. The positive X-ray changes were observed in 50% of patients, and they manifested through the partial resolution of focal infiltrate changes in the lungs. Cessation of bacillary excretion was documented by the end of the second month in 6 patients, by the end of the 3rd month in 1 patient, by the end of the 6th month in 3 patients, totally in 10 out of 12 patients (83.3%). During treatment, all patients had an electrocardiogram, and none of them had prolongation of QT interval.
first_indexed 2024-03-12T03:30:23Z
format Article
id doaj.art-f2620ac4fbdb4b7ab4719e8871fe79fd
institution Directory Open Access Journal
issn 2075-1230
2542-1506
language Russian
last_indexed 2024-03-12T03:30:23Z
publishDate 2017-10-01
publisher New Terra Publishing House
record_format Article
series Туберкулез и болезни лёгких
spelling doaj.art-f2620ac4fbdb4b7ab4719e8871fe79fd2023-09-03T13:29:12ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062017-10-01959495410.21292/2075-1230-2017-95-9-49-541045EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTIONG. S. BALASANYANTS0Военно-медицинская академия им. С. М. КироваThe goal of the study: to evaluate efficiency and safety of the anti-tuberculosis drug of bedaquiline in the multimodality therapy of patients with HIV-associated tuberculosis with multiple/extensive drug resistance (MDR/XDR).Materials and methods. 14 patients were treated with the regimens containing bedaquiline. The majority of patients (12; 85.7%) received antiretroviral therapy. 11 (78.6%) patients were diagnosed with the generalized form of tuberculosis affecting two organs and more. All 14 patients were infectious: 2 had MDR TB and 12 had XDR TB, and of them, 11 had XDR TB with resistance to 8-10 anti-tuberculosis drugs.Results. 12 out of 14 patients completed the intensive phase with administration of bedaquiline. By the end of the first month of treatment intoxication symptoms disappeared in 50.0% of patients, and by the end of the second month, they remitted in 83.5%. The positive X-ray changes were observed in 50% of patients, and they manifested through the partial resolution of focal infiltrate changes in the lungs. Cessation of bacillary excretion was documented by the end of the second month in 6 patients, by the end of the 3rd month in 1 patient, by the end of the 6th month in 3 patients, totally in 10 out of 12 patients (83.3%). During treatment, all patients had an electrocardiogram, and none of them had prolongation of QT interval.https://www.tibl-journal.com/jour/article/view/1045туберкулезсочетанный с вич-инфекциейтуберкулез с множественной лекарственной устойчивостью возбудителябедаквилинпрекращение бактериовыделенияэффективность лечения
spellingShingle G. S. BALASANYANTS
EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION
Туберкулез и болезни лёгких
туберкулез
сочетанный с вич-инфекцией
туберкулез с множественной лекарственной устойчивостью возбудителя
бедаквилин
прекращение бактериовыделения
эффективность лечения
title EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION
title_full EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION
title_fullStr EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION
title_full_unstemmed EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION
title_short EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION
title_sort experience of using bedaquiline in the multimodality therapy of tuberculosis patients with concurrent hiv infection
topic туберкулез
сочетанный с вич-инфекцией
туберкулез с множественной лекарственной устойчивостью возбудителя
бедаквилин
прекращение бактериовыделения
эффективность лечения
url https://www.tibl-journal.com/jour/article/view/1045
work_keys_str_mv AT gsbalasanyants experienceofusingbedaquilineinthemultimodalitytherapyoftuberculosispatientswithconcurrenthivinfection